Maze Therapeutics, Inc. Common Stock (MAZE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.64 Million) by net assets ($379.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Maze Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Maze Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Maze Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
0.011x |
|
East China Engineering Science and Technology Co Ltd
SHE:002140
|
0.088x |
|
Shenzhen Terca Technology Co Ltd
SHE:002213
|
0.047x |
|
Labrador Iron Ore Royalty Corp
TO:LIF
|
0.051x |
|
Siam City Cement Public Company Limited
BK:SCCC
|
0.028x |
|
Yihai International Holding Ltd
F:YIR
|
0.024x |
|
Shanxi Blue Flame Holding Co Ltd
SHE:000968
|
0.040x |
|
S&S TECH Corporation
KQ:101490
|
0.045x |
Annual Cash Flow Conversion Efficiency for Maze Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Maze Therapeutics, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Maze Therapeutics, Inc. Common Stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $196.90 Million | $75.95 Million | 0.386x | +104.47% |
| 2023-12-31 | $10.05 Million | $-86.83 Million | -8.636x | -783.11% |
| 2022-12-31 | $101.44 Million | $-99.20 Million | -0.978x | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidn… Read more